NI201500055A - Tratamiento de cáncer de próstata con inhibidores de quinasa tor - Google Patents

Tratamiento de cáncer de próstata con inhibidores de quinasa tor

Info

Publication number
NI201500055A
NI201500055A NI201500055A NI201500055A NI201500055A NI 201500055 A NI201500055 A NI 201500055A NI 201500055 A NI201500055 A NI 201500055A NI 201500055 A NI201500055 A NI 201500055A NI 201500055 A NI201500055 A NI 201500055A
Authority
NI
Nicaragua
Prior art keywords
prostate cancer
treatment
tor kinase
kinase inhibitors
tor
Prior art date
Application number
NI201500055A
Other languages
English (en)
Inventor
Mortensen Deborah
Raymon Heather
K Narla Rama
Mae Hege Kristen
Elizabeth Fultz Kimberly
Tsuji Toshiya
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of NI201500055A publication Critical patent/NI201500055A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan los métodos para tratar o prevenir cáncer de próstata, que consiste en administrar una cantidad eficaz de un inhibidor de TOR cinasa a un paciente que tenga cáncer de próstata.
NI201500055A 2012-10-18 2015-04-17 Tratamiento de cáncer de próstata con inhibidores de quinasa tor NI201500055A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261715510P 2012-10-18 2012-10-18

Publications (1)

Publication Number Publication Date
NI201500055A true NI201500055A (es) 2015-09-10

Family

ID=50023830

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201500055A NI201500055A (es) 2012-10-18 2015-04-17 Tratamiento de cáncer de próstata con inhibidores de quinasa tor

Country Status (19)

Country Link
US (1) US20140113904A1 (es)
EP (1) EP2908814B1 (es)
JP (3) JP2015534981A (es)
KR (2) KR102267927B1 (es)
CN (2) CN105050601A (es)
AU (1) AU2013202768B2 (es)
BR (1) BR112015008834A2 (es)
CA (1) CA2888609C (es)
EA (1) EA029164B1 (es)
ES (1) ES2777936T3 (es)
IL (1) IL238326B (es)
MX (1) MX368407B (es)
MY (1) MY176599A (es)
NI (1) NI201500055A (es)
PH (1) PH12015500867A1 (es)
SG (2) SG11201502999YA (es)
UA (1) UA117000C2 (es)
WO (1) WO2014062878A2 (es)
ZA (1) ZA201503105B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
WO2014113429A2 (en) 2013-01-16 2014-07-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
EP3131552B1 (en) 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
JP2017520603A (ja) 2014-07-14 2017-07-27 シグナル ファーマシューティカルズ，エルエルシー 置換ピロロピリミジン化合物を使用するがんの治療方法及びその組成物
BR112018010216B1 (pt) * 2015-11-20 2024-02-15 Forma Therapeutics, Inc Purinonas como inibidores da protease específica da ubiquitina 1 e composição farmacêutica compreendendo os referidos compostos
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN110403943B (zh) * 2019-08-19 2022-05-17 陕西科技大学 Cc-115在制备抗真菌药物中的应用及其药物组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159582C (zh) * 2001-12-08 2004-07-28 云南大学 一种人体全血或血清总前列腺特征性抗原值，总前列腺特征性抗原灰区值检测方法
GB0509748D0 (en) 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies
WO2007117653A2 (en) * 2006-04-07 2007-10-18 University Of South Florida Cdk9-pi3k-akt inhibitors for cancer treatment
ATE543819T1 (de) * 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
AU2007309468B2 (en) 2006-10-19 2012-05-17 Signal Pharmaceuticals, Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
EP2349984A1 (en) * 2008-10-17 2011-08-03 Merck & Co. Combination therapy
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
MX341704B (es) * 2009-10-26 2016-08-31 Signal Pharm Llc Métodos de síntesis y purificación de compuestos de heteroarilo.
US20120238562A1 (en) * 2011-03-09 2012-09-20 Cedars-Sinai Medical Center Treatment of cancer by targeting molecules that influence mst1/stk4 signaling

Also Published As

Publication number Publication date
JP7162543B2 (ja) 2022-10-28
BR112015008834A2 (pt) 2017-07-04
EP2908814A2 (en) 2015-08-26
AU2013202768B2 (en) 2015-11-05
EP2908814B1 (en) 2019-12-25
CA2888609A1 (en) 2014-04-24
ZA201503105B (en) 2016-11-30
JP2015534981A (ja) 2015-12-07
CN110721186A (zh) 2020-01-24
KR102267927B1 (ko) 2021-06-21
SG10201810575WA (en) 2019-01-30
KR20150070319A (ko) 2015-06-24
UA117000C2 (uk) 2018-06-11
JP2019081771A (ja) 2019-05-30
KR102157914B1 (ko) 2020-09-18
MX368407B (es) 2019-10-02
PH12015500867B1 (en) 2015-06-22
EA029164B1 (ru) 2018-02-28
MY176599A (en) 2020-08-18
SG11201502999YA (en) 2015-05-28
CN105050601A (zh) 2015-11-11
WO2014062878A3 (en) 2014-06-26
WO2014062878A2 (en) 2014-04-24
ES2777936T3 (es) 2020-08-06
IL238326A0 (en) 2015-06-30
CA2888609C (en) 2020-12-01
AU2013202768A1 (en) 2014-05-08
PH12015500867A1 (en) 2015-06-22
JP2021050213A (ja) 2021-04-01
EA201590744A1 (ru) 2015-11-30
WO2014062878A9 (en) 2014-12-18
IL238326B (en) 2018-03-29
US20140113904A1 (en) 2014-04-24
KR20200108923A (ko) 2020-09-21
MX2015004874A (es) 2015-08-05

Similar Documents

Publication Publication Date Title
NI201400110A (es) Tratamiento del cáncer con inhibidores tor cinasa
PH12018502234A1 (en) Treatment of cancer with tor kinase inhibitors
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
CA2909625C (en) Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
NI201400112A (es) Tratamiento del cáncer con inhibidores tor cinasa
MX357833B (es) Tratamiento del cancer con inhibidores de tor cinasa.
NI201400111A (es) Tratamiento del cáncer con inhibidores tor cinasa
NI201400095A (es) Metodos para el tratamiento del cáncer de pulmon de celulas no pequeñas utilizando terapia combinada de inhibidor tor cinasa.
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
NI201500151A (es) Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata.
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
GT201400038A (es) Composiciones y métodos para tratar el cáncer usando el inhibidor de p13kbeta y el inhibidor de la vía de mapk, incluidos los inhibidores de mek y raf
UY35033A (es) Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa
CR20140480A (es) Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek
NI201300052A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
CO6721062A2 (es) Cmposiciones y métodos para tratar el cancer usando un inhibidor de pi3k y un inhibidor de mek
ECSP13012736A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
GT201300148A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de p13k y un inhibidor de mek
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы